Poseida Therapeutics is a clinical-stage biopharmaceutical company focused on creating cell and gene therapeutics with curative potential. The company employs proprietary gene engineering platform technologies, including a non-viral piggyBac DNA Modification System, the Cas-CLOVER site-specific gene editing system, and nanoparticle- and AAV-based gene delivery technologies. Its pipeline includes both allogeneic and autologous CAR-T product candidates targeting hematological and solid tumor oncology indications, as well as liver-directed gene therapy programs for orphan genetic diseases. Led by CEO Eric Ostertag, M.D., Ph.D., Poseida is advancing a broad portfolio of product candidates across multiple indications. The company intends to use recently raised funds to continue to expand its development efforts. Poseida is a clinical-stage biotechnology company led by CEO Eric Ostertag, M.D., Ph.D., developing a wholly owned pipeline of autologous and allogeneic CAR-T product candidates and gene therapies for orphan genetic diseases. The company has assembled a suite of gene editing technologies, including the piggyBac® DNA Modification System, Cas-CLOVER™, TAL-CLOVER™ site-specific nucleases and Footprint-Free® Gene Editing. Its lead programs include autologous P-BCMA-101 (Phase 2 registrational trial enrolling, initial dosing expected H1 2019) and autologous P-PSMA-101 (IND filing anticipated H2 2019). Poseida is also developing an allogeneic CAR-T, P-BCMA-ALLO1 (IND anticipated late 2019 or early 2020), and a late-stage preclinical solid-tumor candidate, P-MUC1C-101 (IND anticipated 2020). The company plans to broadly advance its current CAR-T programs and its emerging pipeline programs. Financially, Poseida completed a substantial Series C financing to support these development plans. Poseida Therapeutics is a San Diego-based company translating gene engineering technologies into cell therapies. The company develops autologous and allogeneic CAR-T immunotherapies and gene therapies for orphan diseases. Its suite of gene engineering technologies includes the piggyBac DNA Modification System, TAL-CLOVER and Cas-CLOVER site-specific nucleases, and Footprint-Free Gene Editing (FFGE). Lead programs include P-BCMA-101 (Phase 1 for relapsed/refractory multiple myeloma), P-PSMA-101 (preclinical for prostate cancer), and P-BCMA-ALLO1 (an allogeneic "universal donor" CAR-T for multiple myeloma). Poseida is led by CEO Eric Ostertag, M.D., Ph.D. The company will use recent financing to further advance its pipeline of CAR-T and gene therapies. Poseida Therapeutics focuses on developing novel human therapeutics using its proprietary genome engineering platforms, including piggyBac, XTNT TALEN, NextGEN CRISPR nucleases, and Footprint-Free Gene Editing. The company is advancing gene therapies for orphan liver diseases and autologous CAR-T therapies for cancer, with lead candidates targeting Progressive Familial Intraheptatic Cholestasis 3 and multiple myeloma. Poseida also has an alliance with Janssen Biotech to develop allogeneic CAR-T therapies for various cancers. Management states the technologies could enable single-treatment cures and the company emphasizes utility across multiple therapeutic areas. The company is privately held and based in La Jolla, California. No operating metrics (revenue/users) are disclosed in the article.

Total raised

$313M

Funding rounds

4

Latest round

Series D

Latest activity

Jun 2020